Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262913 | 0.83 | ALDH1A1 (0.36) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL6447879 | 0.77 | NUDT1 (0.42) | PTGDR2PTGDRDGAT1ALOX5APFEN1 | |
| SCHEMBL5828071 | 0.77 | HDAC11 (0.41) | — | |
| SCHEMBL4622962 | 0.77 | S1PR1 (0.35) | — | |
| SCHEMBL6449181 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL6449130 | 0.74 | ALOX5AP (0.45) | DGAT1ALOX5APFEN1 | |
| SCHEMBL6449169 | 0.72 | PTGDR2 (0.51) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL7257530 | 0.71 | KDM4E (0.44) | PTGDR2PTGDRCA12CA1CA2 | |
| SCHEMBL7257541 | 0.71 | KDM4E (0.44) | PTGDR2PTGDRCA12CA1CA2 | |
| SCHEMBL7257260 | 0.69 | DRD2 (0.38) | PTGDR2PTGDRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | PTGDR2 941/4885PTGDR 1117/4885SLC6A9 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.